A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prevent NSCLC from coming back after surgery. One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A). Intismeran is designed to help a person's immune system attack their specific cancer. SC pembrolizumab is a

Trial Details

NCT ID

NCT07513376

Phase

PHASE3

Sponsor

Merck Sharp & Dohme LLC

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Intismeran
Pembrolizumab coformulated with berahyaluronidase alfa
Placebo

Locations (sample)

Billings, Montana, United States|45.78329,-108.50069
Lincoln, Nebraska, United States|40.8,-96.66696
Reno, Nevada, United States|39.52963,-119.8138
Grand Forks, North Dakota, United States|47.92526,-97.03285
Knoxville, Tennessee, United States|35.96064,-83.92074

Key Eligibility Criteria

The main inclusion criteria include but are not limited to the following:
Has a histological diagnosis of pathological Stage I (tumor ≤4 cm) non-small cell lung cancer (NSCLC) per American Joint Committee on Cancer (AJCC)…
Has undergone a complete surgical resection of the primary NSCLC
Has not received other prior treatment outside of definitive surgery (including but not limited to chemotherapy, immunotherapy, targeted therapy, o…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →